Posted on 07/12/2024 3:20:23 PM PDT by ConservativeMind
For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a reduced risk for kidney failure with replacement therapy (KFRT) but not death.
Elaine Ku, M.D. and colleagues examined the association of ACEi or ARB treatment initiation with rates of KFRT and death using data from completed randomized controlled trials from 1946 through Dec 31, 2023.
Data were included for 1,739 participants from 18 trials, and of these patients, 35.9 and 7.6 percent developed KFRT and died, respectively, during a median follow-up of 34 months. The researchers found that the risk for KFRT was lower with ACEi or ARB treatment initiation (adjusted hazard ratio, 0.66; 95 percent confidence interval, 0.55 to 0.79), but the risk for death was not significantly lower (adjusted hazard ratio, 0.86; 95 percent confidence interval, 0.58 to 1.28). No significant interactions were seen between ACEi or ARB treatment and age, estimated glomerular filtration rate, albuminuria, or diabetes.
"Initiation of ACEi or ARB therapy protects against KFRT, but not against death, in people with advanced CKD," the authors write. "Even in an era where other agents, such as sodium-glucose cotransporter-2 inhibitors, are available, significant benefit can be derived from the initiation of ACEi or ARB treatment in patients with low glomerular filtration rate."
(Excerpt) Read more at medicalxpress.com ...
Still, an ARB might make life better with a kidney transplant.
ARB’s are probably the best antihypertensive agent, if you can take them.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.